BEGIN:VCALENDAR VERSION:2.0 PRODID:PHP BEGIN:VEVENT DTSTART:20210429 SUMMARY:Triple Negative Breast Cancer Drug Development Digital Summit 2021 DESCRIPTION:
On April 29, 2021, Zenith Epigenetics presented at the Triple Negative Breast Cancer Drug Development Digital Summit 2021, the following: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations."
END:VEVENT END:VCALENDAR